UROGEN PHARMA (NASDAQ:URGN) Expected to Post FY2020 Earnings of $0.35 Per Share

UROGEN PHARMA (NASDAQ:URGN) – Equities researchers at Oppenheimer Holdings increased their FY2020 earnings per share (EPS) estimates for UROGEN PHARMA in a research note issued to investors on Friday. Oppenheimer Holdings analyst D. Archila now forecasts that the company will earn $0.35 per share for the year, up from their previous forecast of $0.25. Oppenheimer Holdings has a “Outperform” rating and a $32.00 price target on the stock. Oppenheimer Holdings also issued estimates for UROGEN PHARMA’s FY2021 earnings at $2.73 EPS.

URGN has been the topic of a number of other reports. Cowen and Company assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set an “outperform” rating on the stock. Jefferies Group LLC assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Raymond James Financial, Inc. assumed coverage on UROGEN PHARMA in a report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price objective on the stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2017/08/11/urogen-pharma-nasdaqurgn-expected-to-post-fy2020-earnings-of-0-35-per-share-updated-updated-updated.html.

Shares of UROGEN PHARMA (URGN) opened at 17.9477 on Monday. The company’s market capitalization is $214.89 million. The stock’s 50 day moving average price is $17.62 and its 200 day moving average price is $17.35. UROGEN PHARMA has a 12-month low of $13.01 and a 12-month high of $20.02.

About UROGEN PHARMA

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

What are top analysts saying about UROGEN PHARMA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for UROGEN PHARMA and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit